Sunshine Lake Pharma Co., Ltd. (HKG:6887)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
41.32
+0.14 (0.34%)
At close: Apr 28, 2026
-10.72%
Market Cap 23.80B
Revenue (ttm) 5.36B
Net Income (ttm) 303.18M
Shares Out 575.98M
EPS (ttm) 0.61
PE Ratio 67.51
Forward PE n/a
Dividend 5.69 (13.88%)
Ex-Dividend Date Jul 31, 2025
Volume 335,756
Average Volume 242,918
Open 41.86
Previous Close 41.18
Day's Range 40.80 - 41.86
52-Week Range 39.80 - 67.30
Beta -0.07
RSI 39.24
Earnings Date Mar 31, 2026

About Sunshine Lake Pharma

Sunshine Lake Pharma Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products for the treatment of infectious diseases, chronic diseases, and oncology. It offers Kewei for the treatment of influenza; Dongweien for the treatment of hepatitis C; and generic drugs for the treatment of infections caused by sensitive bacteria, namely Clarithromycin, Levofloxacin, and Moxifloxacin Hydrochlorid, as well as active pharmaceutical ingredients. The company also engages in the wholesale, retail, import, and export of... [Read more]

Sector Healthcare
Founded 2001
Employees 4,861
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 6887
Full Company Profile

Financial Performance

In 2025, Sunshine Lake Pharma's revenue was 4.82 billion, an increase of 29.31% compared to the previous year's 3.72 billion. Earnings were 272.44 million, a decrease of -43.56%.

Financial numbers in CNY Financial Statements

News

There is no news available yet.